Evidence map›Paper›PMID 30779783›Full record

ArticlePloS one2019

The knocking down of the oncoprotein Golgi phosphoprotein 3 in T98G cells of glioblastoma multiforme disrupts cell migration by affecting focal adhesion dynamics in a focal adhesion kinase-dependent manner.

Cecilia Arriagada, Charlotte Luchsinger, Alexis E González, Tomás Schwenke, Gloria Arriagada, Hugo Folch, Pamela Ehrenfeld, Patricia V Burgos, Gonzalo A Mardones

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Life history and cancer in birds: clutch size predicts cancer.bioRxiv : the preprint server for biology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer.International journal of molecular sciences · 2020
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Cecilia ArriagadaDepartment of Physiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.ORCID 0000-0002-5351-2240
Charlotte LuchsingerDepartment of Physiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.
Alexis E GonzálezDepartment of Physiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.
Tomás SchwenkeDepartmento de Ciencias Biologicas, Facultad de Ciencias de la Vida, Universidad Andres Bello, Viña del Mar, Chile.
Gloria ArriagadaDepartmento de Ciencias Biologicas, Facultad de Ciencias de la Vida, Universidad Andres Bello, Viña del Mar, Chile.
Hugo FolchDepartment of Immunology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.
Pamela EhrenfeldCenter for Interdisciplinary Studies of the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile.
Patricia V BurgosDepartment of Physiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.
Gonzalo A MardonesDepartment of Physiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.ORCID 0000-0001-9390-5893
Austral University of Chile · CLUniversidad Andrés Bello · CLPontificia Universidad Católica de Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Golgi phosphoprotein 3 (GOLPH3) is a conserved protein of the Golgi apparatus that in humans has been implicated in tumorigenesis. However, the precise function of GOLPH3 in malignant transformation is still unknown. Nevertheless, clinicopathological data shows that in more than a dozen kinds of cancer, including gliomas, GOLPH3 could be found overexpressed, which correlates with poor prognosis. Experimental data shows that overexpression of GOLPH3 leads to transformation of primary cells and to tumor growth enhancement. Conversely, the knocking down of GOLPH3 in GOLPH3-overexpressing tumor cells reduces tumorigenic features, such as cell proliferation and cell migration and invasion. The cumulative evidence indicate that GOLPH3 is an oncoprotein that promotes tumorigenicity by a mechanism that impact at different levels in different types of cells, including the sorting of Golgi glycosyltransferases, signaling pathways, and the actin cytoskeleton. How GOLPH3 connects mechanistically these processes has not been determined yet. Further studies are important to have a more complete understanding of the role of GOLPH3 as oncoprotein. Given the genetic diversity in cancer, a still outstanding aspect is how in this inherent heterogeneity GOLPH3 could possibly exert its oncogenic function. We have aimed to evaluate the contribution of GOLPH3 overexpression in the malignant phenotype of different types of tumor cells. Here, we analyzed the effect on cell migration that resulted from stable, RNAi-mediated knocking down of GOLPH3 in T98G cells of glioblastoma multiforme, a human glioma cell line with unique features. We found that the reduction of GOLPH3 levels produced dramatic changes in cell morphology, involving rearrangements of the actin cytoskeleton and reduction in the number and dynamics of focal adhesions. These effects correlated with decreased cell migration and invasion due to affected persistence and directionality of cell motility. Moreover, the knocking down of GOLPH3 also caused a reduction in autoactivation of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase that regulates focal adhesions. Our data support a model in which GOLPH3 in T98G cells promotes cell migration by stimulating the activity of FAK.

Indexed as

Brain NeoplasmsCell Line, TumorCell MovementCell ProliferationFocal Adhesion Protein-Tyrosine KinasesFocal AdhesionsGlioblastomaHumansMembrane ProteinsPhosphorylationRNA InterferenceRNA, Small InterferingFocal Adhesion Protein-Tyrosine KinasesGOLPH3 protein, humanMembrane ProteinsRNA, Small Interfering

Identifiers

PMID30779783
PMCPMC6380552
OpenAlexW2917101129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.